Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Virus-like and Virus Replicon Particles Targeting Multiple B-Cell Antigens Do Not Protect Against African Swine Fever Virus.

Vaccines·2026
Same author

A Case for Anti-IgE Vaccination.

Allergy·2026
Same author

Targeted Lymph Node Immunization with Serotype-Specific Dengue VLP Vaccines Enhances Antibody Avidity and Specificity.

Vaccines·2025
Same author

Versatile and Scalable Nanoparticle Vaccine as a Scaffold Against Newly Emerging Influenza Viruses.

Viruses·2025
Same author

IgE in the Regulation of Adaptive Immune Responses.

Immunological reviews·2025
Same author

Vaccine-Induced Anti-IgE Antibodies Neutralize Free IgE but Fail to Bind and Activate Mast Cell-Displayed IgE.

Allergy·2025

Related Experiment Video

Updated: Dec 12, 2025

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

4.0K

Special Issue "Virus-Like Particle Vaccines".

Monique Vogel1,2, Martin F Bachmann1,2,3

  • 1University Hospital for Rheumatology, Immunology, and Allergology, University of Bern, 3010 Bern, Switzerland.

Viruses
|August 14, 2020
PubMed
Summary

Virus-like particles (VLPs) are crucial for vaccine development. They offer a versatile platform for creating effective and safe vaccines against various diseases.

More Related Videos

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.5K
Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses
08:10

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Published on: January 15, 2020

8.7K

Related Experiment Videos

Last Updated: Dec 12, 2025

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

4.0K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.5K
Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses
08:10

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Published on: January 15, 2020

8.7K

Area of Science:

  • Biotechnology
  • Vaccinology
  • Structural Biology

Background:

  • Virus-like particles (VLPs) are emerging as a significant platform in modern vaccinology.
  • Their self-assembling, non-infectious nature makes them ideal vaccine candidates.

Discussion:

  • VLPs mimic the structure of native viruses, eliciting robust immune responses.
  • Their modularity allows for the incorporation of diverse antigens, broadening vaccine applicability.

Key Insights:

  • VLP technology facilitates rapid vaccine design and manufacturing.
  • VLPs have demonstrated efficacy in preclinical and clinical studies for various pathogens.

Outlook:

  • Further research into VLP immunomodulation and delivery systems will enhance their therapeutic potential.
  • VLPs are poised to play a pivotal role in addressing future infectious disease outbreaks.